In KrasLSL-G12D/+SIRPGKI/+ compound mice treated with SIRPγ-blocking antibody, we found that targeting SIRPγ by LSB2.20 reduced the in vivo tumor growth of lung adenoma compared with the anti-IgG–treated group (Figure 11, D and E). Here, SIRPG is linked to neoplasm.